Gland Pharma shares rally 6% as brokerages lift ratings, target prices; here's why

Gland Pharma shares surged after strong Q1 results and positive commentary from brokerages citing a turnaround at its European unit Cenexi. EBITDA margins expanded to 24.4%, and net profit rose 50% YoY. Despite weak U.S. sales, growth in Europe and new launches supported the outlook. Brokerages raised earnings estimates and targets, expecting further gains as Cenexi scales profitability.